Experts attending the European Psychiatry Association Congress in Vienna say that Adasuve has made an impact in the treatment of agitation in patients suffering from schizophrenia or bipolar I disorder.
Adasuve, an oral inhalation product that combines the patented Staccato system with the antipsychotic loxapine, was approved by EMA in February 2013. The formulation has since benefitted 5000 patients in Europe, according to Rudolf Widmann, CEO of AOP Orphan, speaking at the European Psychiatry Association Congress in Vienna. Experts at the event also confirmed that Adasuve has made an impact in the treatment of agitation in patients suffering from schizophrenia or biopolar I disorder.
In the Staccato system, loxapine is evaporated to produce an aerosol that is absorbed by the lungs. The drug is transported into the systemic circulation through the lungs, and patients notice a decrease in agitation within 10 minutes.
Available in doses of 9.1 mg, Adasuve is indicated to control cases of mild or moderate agitation in patients suffering from schizophrenia or bipolar I disorder. Patients prefer this non-invasive treatment option to an injection.
